Gastric AdenocarcinomaNCT06614439
PG Versus TG for Advanced PGC
A study testing proximal gastrectomy and total gastrectomy in people with Gastric Adenocarcinoma and Gastrectomy, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
We conducted a retrospective study on patients with pathological stage II-III PGC who underwent PG or TG from 2013 to 2023. Propensity score-matching was applied to adjust for tumor size and stage between the PG and TG groups at a 1:1 ratio. We evaluated the procedural safety, oncological, and functional outcomes. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Gastric Adenocarcinoma, Gastrectomy
- What is being tested?
- proximal gastrectomy and total gastrectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteTaiwan
- Study dates
- 4 Sep 2024to 1 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Proximal gastric adenocarcinoma after total or proximal gastrectomy.
Who cannot join
- Non-curative resections
- Non-adenocarcinoma histology
- Distally located tumors or middle/proximally located tumors for which distal margin could not be secured by PG
- Remnant gastric cancer
- Clinically T1N0 tumors smaller than 3 cm for which PG was clearly indicated
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
National Taiwan University Hospital Hsin-Chu Branch
Hsin-Chu County, 302
About this study
Official title: Proximal Versus Total Gastrectomy for Advanced Proximal Gastric Cancer: A Retrospective Double-Center Propensity Score-Matched Cohort Study
We conducted a retrospective study on patients with pathological stage II-III PGC who underwent PG or TG from 2013 to 2023. Propensity score-matching was applied to adjust for tumor size and stage between the PG and TG groups at a 1:1 ratio. We evaluated the procedural safety, oncological, and functional outcomes.
- Conditions
- Gastric Adenocarcinoma, Gastrectomy
- Being tested
- proximal gastrectomy, total gastrectomy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
proximal gastrectomyProcedure or surgery
proximal gastrectomy
total gastrectomyProcedure or surgery
total gastrectomy
| Study group | Role | What they receive |
|---|---|---|
| Proximal gastrectomy | Experimental | Not described Receives: Procedure: proximal gastrectomy |
| Total gastrectomy | Active comparator | Not described Receives: Procedure: total gastrectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
five-year overall survival
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2024
- Study start4 Sep 2024
- Primary completion1 Aug 2025
- Study completion1 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Gastric AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 96 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06614439
- Sponsor's protocol ID
- 202408135RIND
- Status last verified
- Sep 2024
- First submitted
- 23 Sep 2024
- Last updated
- 18 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Lee S, Chae YS, Yun WG, Kim JC, Park JK, Kim MG, Kim J, Cho YS, Kong SH, Park DJ, Lee HJ, Yang HK. Long-Term Outcome of Proximal Gastrectomy for Upper-Third Advanced Gastric and Siewert Type II Esophagogastric Junction Cancer Compared With Total Gastrectomy: A Propensity Score-Matched Analysis. Ann Surg Oncol. 2024 May;31(5):3024-3030. doi: 10.1245/s10434-024-15048-8. Epub 2024 Feb 19.
PubMed 38372863Peng R, Yue C, Wei W, Zhou B, Wen X, Gu RM, Ming XZ, Li G, Chen HQ, Xu ZK. Proximal gastrectomy may be a reasonable choice for patients with selected proximal advanced gastric cancer: A propensity score-matched analysis. Asian J Surg. 2022 Oct;45(10):1823-1831. doi: 10.1016/j.asjsur.2021.09.029. Epub 2021 Oct 9.
PubMed 34642056Rosa F, Quero G, Fiorillo C, Bissolati M, Cipollari C, Rausei S, Chiari D, Ruspi L, de Manzoni G, Costamagna G, Doglietto GB, Alfieri S. Total vs proximal gastrectomy for adenocarcinoma of the upper third of the stomach: a propensity-score-matched analysis of a multicenter western experience (On behalf of the Italian Research Group for Gastric Cancer-GIRCG). Gastric Cancer. 2018 Sep;21(5):845-852. doi: 10.1007/s10120-018-0804-3. Epub 2018 Feb 8.
PubMed 29423892Sugoor P, Shah S, Dusane R, Desouza A, Goel M, Shrikhande SV. Proximal gastrectomy versus total gastrectomy for proximal third gastric cancer: total gastrectomy is not always necessary. Langenbecks Arch Surg. 2016 Aug;401(5):687-97. doi: 10.1007/s00423-016-1422-3. Epub 2016 May 4.
PubMed 27143021Lee S, Son WJ, Roh YH, Song JH, Park SH, Cho M, Kim YM, Hyung WJ, Kim HI. Indication of Proximal Gastrectomy for Advanced Proximal Gastric Cancer Based on Lymph Node Metastasis at the Distal Part of the Stomach. Ann Surg Open. 2021 Nov 24;2(4):e107. doi: 10.1097/AS9.0000000000000107. eCollection 2021 Dec.
PubMed 37637877
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Proximal Versus Total Gastrectomy for Advanced Proximal Gastric Cancer: A Retrospective Double-Center Propensity Score-Matched Cohort Study
- ClinicalTrials.gov ID
- NCT06614439
- Acronym / sponsor ID
- 202408135RIND
- Conditions
- Gastric Adenocarcinoma, Gastrectomy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 96 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 4 Sep 2024 (actual)
- Primary completion
- 1 Aug 2025 (actual)
- Study completion
- 1 Sep 2025 (actual)
- First posted
- 26 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We conducted a retrospective study on patients with pathological stage II-III PGC who underwent PG or TG from 2013 to 2023. Propensity score-matching was applied to adjust for tumor size and stage between the PG and TG groups at a 1:1 ratio. We evaluated the procedural safety, oncological, and functional outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Proximal gastrectomy | Experimental | Procedure: proximal gastrectomy |
| Total gastrectomy | Active comparator | Procedure: total gastrectomy |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Proximal gastric adenocarcinoma after total or proximal gastrectomy.
Key exclusion criteria (5 listed)
- Non-curative resections
- Non-adenocarcinoma histology
- Distally located tumors or middle/proximally located tumors for which distal margin could not be secured by PG
- Remnant gastric cancer
- Clinically T1N0 tumors smaller than 3 cm for which PG was clearly indicated
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| proximal gastrectomyproximal gastrectomy | Procedure or surgery | Proximal gastrectomy |
| total gastrectomytotal gastrectomy | Procedure or surgery | Total gastrectomy |
Primary outcome
five-year overall survival
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
- Background: PubMed 38372863Lee S, Chae YS, Yun WG, Kim JC, Park JK, Kim MG, Kim J, Cho YS, Kong SH, Park DJ, Lee HJ, Yang HK. Long-Term Outcome of Proximal Gastrectomy for Upper-Third Advanced Gastric and Siewert Type II Esophagogastric Junction Cancer Compared With Total Gastrectomy: A Propensity Score-Matched Analysis. Ann Surg Oncol. 2024 May;31(5):3024-3030. doi: 10.1245/s10434-024-15048-8. Epub 2024 Feb 19.
- Background: PubMed 34642056Peng R, Yue C, Wei W, Zhou B, Wen X, Gu RM, Ming XZ, Li G, Chen HQ, Xu ZK. Proximal gastrectomy may be a reasonable choice for patients with selected proximal advanced gastric cancer: A propensity score-matched analysis. Asian J Surg. 2022 Oct;45(10):1823-1831. doi: 10.1016/j.asjsur.2021.09.029. Epub 2021 Oct 9.
- Background: PubMed 29423892Rosa F, Quero G, Fiorillo C, Bissolati M, Cipollari C, Rausei S, Chiari D, Ruspi L, de Manzoni G, Costamagna G, Doglietto GB, Alfieri S. Total vs proximal gastrectomy for adenocarcinoma of the upper third of the stomach: a propensity-score-matched analysis of a multicenter western experience (On behalf of the Italian Research Group for Gastric Cancer-GIRCG). Gastric Cancer. 2018 Sep;21(5):845-852. doi: 10.1007/s10120-018-0804-3. Epub 2018 Feb 8.
- Background: PubMed 27143021Sugoor P, Shah S, Dusane R, Desouza A, Goel M, Shrikhande SV. Proximal gastrectomy versus total gastrectomy for proximal third gastric cancer: total gastrectomy is not always necessary. Langenbecks Arch Surg. 2016 Aug;401(5):687-97. doi: 10.1007/s00423-016-1422-3. Epub 2016 May 4.
- Background: PubMed 37637877Lee S, Son WJ, Roh YH, Song JH, Park SH, Cho M, Kim YM, Hyung WJ, Kim HI. Indication of Proximal Gastrectomy for Advanced Proximal Gastric Cancer Based on Lymph Node Metastasis at the Distal Part of the Stomach. Ann Surg Open. 2021 Nov 24;2(4):e107. doi: 10.1097/AS9.0000000000000107. eCollection 2021 Dec.
- Individual participant dataSharing planned: Undecided
Related trials for Gastric Adenocarcinoma
RecruitingPhase 1
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Not yet recruitingObservational study
MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastrointestinal Cancers
Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors
RecruitingPhase 1
DBC-664 in Adult Patients With Solid Tumors
Malignant Germ Cell Tumor, Lung Adenocarcinoma
Not yet recruitingPhase 1/2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors.
Advanced Solid Tumors, Gastric Cancer (GC)
Not yet recruitingPhase 1/2
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing proximal gastrectomy and total gastrectomy in people with Gastric Adenocarcinoma and Gastrectomy, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
five-year overall survival (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06614439, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025; AzTrials last refreshed its copy on 28 Oct 2026.